The development of mesna for regional detoxification

Bertino, 1979, Toward improved selectivity in cancer chemotherapy: The Richard and Hinda rosenthal foundation award lecture, Cancer Res., 39, 293

Brock, 1980, Konzeption und Wirkmechanismus von Uromitexan (Mesna), 1

Brock, 1982, Mesna (Natrium-2-mercapto-äthan-sulfonat). Prophylaxc der akuten urotoxischen Nebenwirkungen sowie der kanzerogenen Spätfolgen von Cyclophosphamid und Ifosfamid, Therapiewoche, 32, 4977

Brock, 1981, Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—I. Experimental studies on the urotoxicity of alkylating compounds, Eur. J. Cancer, 17, 596, 10.1016/S0277-5379(81)80019-3

Brock, 1981, Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds, Eur. J. Cancer Clin. Oncol., 17, 1155, 10.1016/S0277-5379(81)80019-3

Brock, 1982, Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—3. Profile of action of sodium 2-mercaptoethane sulfonate (mesna), Eur. J. Cancer Clin. Oncol., 18, 1377, 10.1016/0277-5379(82)90143-2

Brock, 1979, Acrolein, the causative factor of urotoxic side effects of cyclophosphamide, ifosfamide, trofosfamide, and sufosfamide, Arzneim. Forsch. (Drug Res.), 29, 659

Bryant, 1982, Simultaneous infusion of 2-mercaptoethane sulphonate sodium (mesna) during continuous 24 hour administration of ifosfamide

Burkert, 1979, Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen “Uroprotektor”, Münch. med. Woschenschr., 121, 760

Goldin, 1954, Effect of delayed administration of citrovorum factor on the anti-leukemic effectiveness of aminopterin in mice, Cancer Res, 14, 43

Klein, 1982, High-dose ifosfamide (IFO) and mesna as continuous infusion over five days—a phase I/II trial

Klein, 1981, Experimental and clinical investigations on the role of mesna (MS) in cytostatic therapy with oxazaphosphorines, S. 86

Kunze, 1980, Proliferationskinetik regenerierender Urothelzellen in der Rattenharnblase nach Applikation von Cyclophosphamid, Virchows Arch. B. Cell Pathol., 33, 47, 10.1007/BF02899170

Link, 1981, Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation, Blut, 43, 329, 10.1007/BF00320957

Philips, 1961, Cyclophosphamide and urinary bladder toxicity, Cancer Res., 21, 1577

Ormstadt, 1983, Pharmacokinetics and metabolism of sodium 2-mercaptoethane sulfonate (mesna) in the rat, Cancer Res., 43, 333

Scheef, 1981, Clinical experience with mesna (Uromitexan®), 85

Vahlensiek, 1974, Zur Pathogenese, Klinik und Prophylaxe der sogenannten Cyclophosphamid-Zystitis, Münch. med. Wochenschr., 116, 1889

Wiltshaw, 1982, Single agent ifosfamide plus mesna for metastatic soft tissue sarcoma